Expression of PAR-4 and PHLDA1 is prognostic for overall and disease-free survival in oral squamous cell carcinomas

Virchows Archiv

Volumn 463, Issue 1, 2013, Pages 31-39

  Coutinho Camillo, Cláudia Malheiros ^a   Lourenço, Silvia Vanessa ^b   Nonogaki, Suely ^a   Vartanian, José Guilherme ^a   Nagai, Maria Aparecida ^b   Kowalski, Luiz Paulo ^a   Soares, Fernando Augusto ^a,b  

^a A C CAMARGO CANCER CENTER   (Brazil)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Immunohistochemistry; Oral squamous cell carcinoma; PAR 4; PHLDA1; Tissue microarray

Indexed keywords

PLECKSTRIN; PLECKSTRIN HOMOLOGY LIKE DOMAIN FAMILY A1; PROTEINASE ACTIVATED RECEPTOR 4; UNCLASSIFIED DRUG;

ADULT; ARTICLE; ASSOCIATION; CANCER PATIENT; CANCER PROGNOSIS; CANCER SPECIFIC SURVIVAL; CANCER STAGING; CANCER SURVIVAL; CLINICAL FEATURE; DISEASE ASSOCIATION; DISEASE FREE SURVIVAL; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MOUTH SQUAMOUS CELL CARCINOMA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SURVIVAL RATE; TISSUE MICROARRAY;

ADULT; AGED; APOPTOSIS REGULATORY PROTEINS; CARCINOMA, SQUAMOUS CELL; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; MOUTH NEOPLASMS; PROGNOSIS; TISSUE ARRAY ANALYSIS; TRANSCRIPTION FACTORS;

EID: 84879840135     PISSN: 09456317     EISSN: 14322307     Source Type: Journal    
DOI: 10.1007/s00428-013-1438-9     Document Type: Article

References (35)

1. Massano J, Regateiro FS, Januário G, Ferreira A (2006) Oral Squamous cell carcinoma: review of prognostic and predictive factors. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 102:67-76
2. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012 (2012) CA Cancer J Clin 62(1):10-29
3. da Saúde M (2011) Ministério da Saúde. Instituto Nacional do Câncer. Estimativa/2012. Incidência de Câncer no Brasil. Rio de. Janeiro, INCA
4. Schoelch ML, Le QT, Silverman S Jr, McMillan A, Dekker NP, Fu KK, Ziober BL, Regezi JA (1999) Apoptosis-associated proteins and the development of oral squamous cell carcinoma. Oral Oncol 35(1):77-85
5. Coutinho-Camillo CM, Lourenço SV, Nishimoto IN, Kowalski LP, Soares FA (2010) Expression of Bcl-2 family proteins and association with clinicopathological characteristics of oral squamous cell carcinoma. Histopathology 57(2):304-316
6. Coutinho-Camillo CM, Lourenço SV, Nishimoto IN, Kowalski LP, Soares FA (2011) Caspase expression in oral squamous cell carcinoma. Head Neck 33(8):1191-1198
7. Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144(5):646-674
8. Hanahan D, Weinberg RA (2000) The hallmarks of cancer. Cell 100(1):57-70
9. Zhao Y, Rangnekar VM (2008) Apoptosis and tumor resistance conferred by Par-4. Cancer Biol Ther 7:1867-1874
10. Cook J, Krishnan S, Ananth S, Sells SF, Shi Y, Walther MM, Linehan WM, Sukhatme VP, Weinstein MH, Rangnekar VM (1999) Decreased expression of the pro-apoptotic protein Par-4 in renal cell carcinoma. Oncogene 18:1205-1208
11. Kogel D, Reimertz C, Mech P, Poppe M, Fruhwald MC, Engemann H, Scheidtmann KH, Prehn JH (2001) Dlk/ZIP kinase-induced apoptosis in human medulloblastoma cells: requirement of the mitochondrial apoptosis pathway. Br J Cancer 85:1801-1808
12. Boehrer S, Chow KU, Puccetti E, Ruthardt M, Godzisard S, Krapohl A, Schneider B, Hoelzer D, Mitrou PS, Rangnekar VM, Weidmann E lymphocytes and inverse expressional patterns of par-4 and bcl-2 in acute lymphocytic leukemia. Hematol J 2:103-107
13. Nagai MA, Gerhard R, Salaorni S, Fregnani JH, Nonogaki S, Netto MM, Soares FA (2010) Down-regulation of the candidate tumor suppressor gene PAR-4 is associated with poor prognosis in breast cancer. Int J Oncol 37(1):41-49
14. Moreno-Bueno G, Fernandez-Marcos PJ, Collado M, Tendero MJ, Rodriguez-Pinilla SM, Garcia-Cao I, Hardisson D, Diaz-Meco MT, Moscat J, Serrano M, Palacios J (2007) Inactivation of the candidate tumor suppressor par-4 in endometrial cancer. Cancer Res 67:1927-1934
15. Lee JW, Hsiao WT, Lee KF, Sheu LF, Hsu HY, Hsu SB, Lee MS, Hsu YC, Chang CH (2010) Widespread expression of prostate apoptosis response-4 in nasopharyngeal carcinoma. Head Neck 32(7):877-885
16. Frank D, Mendelsohn CL, Ciccone E, Svensson K, Ohlsson R, Tycko B (1999) A novel pleckstrin homology-related gene family defined by Ipl/Tssc3, TDAG51, and Tih1: tissue-specific expression, chromosomal location, and parental imprinting. Mamm Genome 10(12):1150-1159
17. Park CG, Lee SY, Kandala G, Lee SY, Choi Y (1996) A novel gene product that couples TCR signaling to Fas(CD95) expression in activation-induced cell death. Immunity 4(6):583-591
18. Gomes I, Xiong W, Miki T, Rosner MR (1999) A proline- and glutamine-rich protein promotes apoptosis in neuronal cells. J Neurochem 73(2):612-622
19. Hossain GS, van Thienen JV, Werstuck GH, Zhou J, Sood SK, Dickhout JG, de Koning AB, Tang D, Wu D, Falk E, Poddar R, Jacobsen DW, Zhang K, Kaufman RJ, Austin RC (2003) TDAG51 is induced by homocysteine, promotes detachment-mediated programmed cell death, and contributes to the development of atherosclerosis in hyperhomocysteinemia. J Biol Chem 278(32):30317-30327
20. Neef R, Kuske MA, Pröls E, Johnson JP (2002) Identification of the human PHLDA1/TDAG51 gene: down-regulation in metastatic melanoma contributes to apoptosis resistance and growth deregulation. Cancer Res 62:5920-5929
21. Nagai MA, Fregnani JHTG, Netto MM, Brentani MM, Soares FA (2007) Down-regulation of PHLDA1 gene expression is associated with breast cancer progression. Breast Cancer Res Treat 106:49-56
22. Shrestha-Bhattarai T, Rangnekar VM (2010) Cancer-selective apoptotic effects of extracellular and intracellular Par-4. Oncogene 29(27):3873-3880
23. Goswami A, Ranganathan P, Rangnekar VM (2006) The phosphoinositide 3-kinase/Akt1/Par-4 axis: a cancer-selective therapeutic target. Cancer Res 66(6):2889-2892
24. Qiu G, Ahmed M, Sells SF, Mohiuddin M, Weinstein MH, Rangnekar VM (1999) Mutually exclusive expression patterns of Bcl-2 and Par-4 in human prostate tumors consistent with down-regulation of Bcl-2 by Par-4. Oncogene 18(3):623-631
25. Burikhanov R, Zhao Y, Goswami A, Qiu S, Schwarze SR, Rangnekar VM (2009) The tumor suppressor Par-4 activates an extrinsic pathway for apoptosis. Cell 138(2):377-388
26. Sharma AK, Kline CL, Berg A, Amin S, Irby RB (2011) The Akt Inhibitor Isc-4 Activates Prostate Apoptosis Response Protein-4 and Reduces Colon Tumor Growth in a Nude Mouse Model. Clin Cancer Res 17(13):4474-4483
27. Chaudhry P, Singh M, Parent S, Asselin E (2012) Prostate Apoptosis Response-4 (Par-4): A Novel Substrate of Caspase-3 during Apoptosis Activation. Mol Cell Biol 32(4):826-839
28. Oberst MD, Beberman SJ, Zhao L, Yin JJ, Ward Y, Kelly K (2008) TDAG51 is an ERK signaling target that opposes ERK-mediated HME16C mammary epithelial cell transformation. BMC Cancer 8:189
29. Toyoshima Y, Karas M, Yakar S, Dupont J, Lee H, LeRoith D (2004) TDAG51 mediates the effects of insulin-like growth factor I (IGF-I) on cell survival. J Biol Chem 279:25898-25904
30. Oberg HH, Sipos B, Kalthoff H, Janssen O, Kabelitz D (2004) Regulation of T-cell death-associated gene 51 (TDAG51) expression in human T-cells. Cell Death Differ 11(6):674-684
31. Johnson EO, Chang KH, de Pablo Y, Ghosh S, Mehta R, Badve S, Shah K (2011) PHLDA1 is a crucial negative regulator and effector of Aurora A kinase in breast cancer. J Cell Sci 124(Pt 16):2711-2722
32. Sakthianandeswaren A, Christie M, D'Andreti C, Tsui C, Jorissen RN, Li S, Fleming NI, Gibbs P, Lipton L, Malaterre J, Ramsay RG, Phesse TJ, Ernst M, Jeffery RE, Poulsom R, Leedham SJ, Segditsas S, Tomlinson IP, Bernhard OK, Simpson RJ, Walker F, Faux MC, Church N, Catimel B, Flanagan DJ, Vincan E, Sieber OM (2011) PHLDA1 Expression Marks the Putative Epithelial Stem Cells and Contributes to Intestinal Tumorigenesis. Cancer Res 71(10):3709-3719
33. Ohyama M, Terunuma A, Tock CL, Radonovich MF, Pise-Masison CA, Hopping SB, Brady JN, Udey MC, Vogel JC (2006) Characterization and isolation of stem cell-enriched human hair follicle bulge cells. J Clin Invest 116:249-260
34. Sellheyer K (2011) Stem cell markers can help identify adnexal tumor differentiation when evaluated in the context of morphology: methodology matters. J Cutan Pathol 38(6):460-474
35. Sellheyer K, Nelson P (2011) Follicular stem cell marker PHLDA1 (TDAG51) is superior to cytokeratin-20 in differentiating between trichoepithelioma and basal cell carcinoma in small biopsy specimens. J Cutan Pathol 38:542-550